CB2/Cannabinoid Receptor 2/CNR2 Antibody (B-6): sc-518269

CB2 Antibody (B-6) is a monoclonal antibody that recognizes CB2 protein in human, mouse, and rat samples through western blotting (WB), immunofluorescence (IF), and immunoprecipitation (IP). Anti-CB2 antibody (B-6) enables research into CB2, a cannabinoid receptor family member essential for endocannabinoid system function, which regulates pain sensation, mood, and immune response. CB2 monoclonal antibody (B-6) supports studies of inflammation and neuroprotection mechanisms, making CB2 a promising therapeutic target for chronic pain, neurodegenerative diseases, and autoimmune disorders. CB2 (B-6) antibody helps researchers examine CB2′s unique expression in immune cells and peripheral tissues, highlighting CB2′s role in mediating cannabinoid effects outside the central nervous system. CB2 (B-6) monoclonal antibody serves as a valuable research tool for exploring cannabinoid signaling pathways and developing treatments that avoid psychoactive effects associated with other cannabinoid receptors.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CB2/Cannabinoid Receptor 2/CNR2 Antibody (B-6) References:

1. CB2 receptors as new therapeutic targets for liver diseases.  |  Lotersztajn, S., et al. 2008. Br J Pharmacol. 153: 286-9. PMID: 17952109
2. CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease.  |  Aso, E. and Ferrer, I. 2016. Front Neurosci. 10: 243. PMID: 27303261
3. CB2 receptor activation inhibits the phagocytic function of microglia through activating ERK/AKT-Nurr1 signal pathways.  |  Han, QW., et al. 2022. Acta Pharmacol Sin. 43: 2253-2266. PMID: 35132190
4. Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Celiac Disease.  |  Tortora, C., et al. 2022. Biomedicines. 10: PMID: 35453624
5. Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1.  |  Ten-Blanco, M., et al. 2022. Biomed Pharmacother. 149: 112925. PMID: 35477218
6. Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders.  |  Morcuende, A., et al. 2022. Front Psychiatry. 13: 866052. PMID: 35492718
7. Roles of cannabinoid CB1 and CB2 receptors in the modulation of psychostimulant responses.  |  Gobira, PH., et al. 2024. Acta Neuropsychiatr. 36: 67-77. PMID: 35993329
8. CB2 Receptor as Emerging Anti-Inflammatory Target in Duchenne Muscular Dystrophy.  |  Argenziano, M., et al. 2023. Int J Mol Sci. 24: PMID: 36834757
9. Cannabinoid CB2 receptors and hypersensitivity to methamphetamine: Vulnerability to schizophrenia.  |  Canseco-Alba, A., et al. 2024. Prog Neuropsychopharmacol Biol Psychiatry. 130: 110924. PMID: 38135096
10. CB2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions.  |  Grabon, W., et al. 2024. J Neuroinflammation. 21: 206. PMID: 39160534
11. Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation.  |  Hosoki, H., et al. 2024. Life Sci. 355: 123002. PMID: 39173999
12. Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling.  |  Navarro, G., et al. 2024. Pharmacol Res. 208: 107363. PMID: 39179054

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CB2/Cannabinoid Receptor 2/CNR2 Antibody (B-6) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-CB2/Cannabinoid Receptor 2/CNR2 Antibody (B-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CB2/Cannabinoid Receptor 2/CNR2 Antibody (B-6) Specifications

Alternate Product Name: CB2

Product Clone Name: B-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 331-357

Epitope Target: CB2

Epitope Species: human

Product Reactivity/Detection: CB2

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for CB2/Cannabinoid Receptor 2/CNR2 Antibody (B-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin